Win Aung Ko, Reece Jeanette C, Buchanan Daniel D, Clendenning Mark, Young Joanne P, Cleary Sean P, Kim Hyeja, Cotterchio Michelle, Dowty James G, MacInnis Robert J, Tucker Katherine M, Winship Ingrid M, Macrae Finlay A, Burnett Terrilea, Le Marchand Loïc, Casey Graham, Haile Robert W, Newcomb Polly A, Thibodeau Stephen N, Lindor Noralane M, Hopper John L, Gallinger Steven, Jenkins Mark A
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie Street, Parkville, VIC, 3010, Australia.
Oncogenomics Group, Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, VIC, Australia.
Fam Cancer. 2015 Dec;14(4):575-83. doi: 10.1007/s10689-015-9824-x.
The base excision repair protein, MUTYH, functionally interacts with the DNA mismatch repair (MMR) system. As genetic testing moves from testing one gene at a time, to gene panel and whole exome next generation sequencing approaches, understandin g the risk associated with co-existence of germline mutations in these genes will be important for clinical interpretation and management. From the Colon Cancer Family Registry, we identified 10 carriers who had both a MUTYH mutation (6 with c.1187G>A p.(Gly396Asp), 3 with c.821G>A p.(Arg274Gln), and 1 with c.536A>G p.(Tyr179Cys)) and a MMR gene mutation (3 in MLH1, 6 in MSH2, and 1 in PMS2), 375 carriers of a single (monoallelic) MUTYH mutation alone, and 469 carriers of a MMR gene mutation alone. Of the 10 carriers of both gene mutations, 8 were diagnosed with colorectal cancer. Using a weighted cohort analysis, we estimated that risk of colorectal cancer for carriers of both a MUTYH and a MMR gene mutation was substantially higher than that for carriers of a MUTYH mutation alone [hazard ratio (HR) 21.5, 95% confidence interval (CI) 9.19-50.1; p < 0.001], but not different from that for carriers of a MMR gene mutation alone (HR 1.94, 95% CI 0.63-5.99; p = 0.25). Within the limited power of this study, there was no evidence that a monoallelic MUTYH gene mutation confers additional risk of colorectal cancer for carriers of a MMR gene mutation alone. Our finding suggests MUTYH mutation testing in MMR gene mutation carriers is not clinically informative.
碱基切除修复蛋白MUTYH在功能上与DNA错配修复(MMR)系统相互作用。随着基因检测从一次检测一个基因,转向基因panel和全外显子组下一代测序方法,了解这些基因中种系突变共存所带来的风险对于临床解读和管理至关重要。在结肠癌家族登记处,我们鉴定出10名同时携带MUTYH突变(6名携带c.1187G>A p.(Gly396Asp),3名携带c.821G>A p.(Arg274Gln),1名携带c.536A>G p.(Tyr179Cys))和MMR基因突变(3名在MLH1,6名在MSH2,1名在PMS2)的携带者,375名单独携带单等位基因MUTYH突变的携带者,以及469名单独携带MMR基因突变的携带者。在这10名同时携带两种基因突变的携带者中,8名被诊断患有结直肠癌。通过加权队列分析,我们估计同时携带MUTYH和MMR基因突变的携带者患结直肠癌的风险显著高于单独携带MUTYH突变的携带者[风险比(HR)21.5,95%置信区间(CI)9.19 - 50.1;p < 0.001],但与单独携带MMR基因突变的携带者没有差异(HR 1.94,95% CI 0.63 - 5.99;p = 0.25)。在本研究有限的检验效能范围内,没有证据表明单等位基因MUTYH基因突变会给单独携带MMR基因突变的携带者带来额外的结直肠癌风险。我们的研究结果表明,对MMR基因突变携带者进行MUTYH突变检测在临床上并无实际意义。
J Natl Cancer Inst. 2015-6-24
Hum Genet. 2006-3
Genes Chromosomes Cancer. 2020-7-2
DNA Repair (Amst). 2019-6-8
Int J Cancer. 2016-10-1
Gastroenterology. 2014-1-17
Hum Mutat. 2013-3
J Mol Diagn. 2010-12-23
Clin Cancer Res. 2010-10-5
Hered Cancer Clin Pract. 2005-5-15